Glymphatic System Disruption

Target: AQP4 Composite Score: 0.455 Price: $0.52▲4.7% Citation Quality: Pending clinical neurology Status: active
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
3
Opposing
Quality Report Card click to collapse
C
Composite: 0.455
Top 73% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.50 Top 76%
C+ Evidence Strength 15% 0.50 Top 57%
C+ Novelty 12% 0.50 Top 82%
C+ Feasibility 12% 0.50 Top 65%
F Impact 12% 0.00 Top 50%
C+ Druggability 10% 0.50 Top 57%
C+ Safety Profile 8% 0.50 Top 57%
C+ Competition 6% 0.50 Top 77%
C+ Data Availability 5% 0.50 Top 71%
C+ Reproducibility 5% 0.50 Top 63%
Evidence
5 supporting | 3 opposing
Citation quality: 0%
Debates
1 session B+
Avg quality: 0.79
Convergence
0.00 F 10 related hypothesis share this target

From Analysis:

Why do systemic anti-inflammatory drugs fail in AD despite cardiovascular efficacy if neuroinflammation is central?

The debate noted clinical failures of TNF-α and IL-6 inhibitors in AD despite their cardiovascular success and shared inflammatory pathways. This paradox suggests unknown mechanistic differences that could inform therapeutic design. Source: Debate session sess_SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404 (Analysis: SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404)

→ View full analysis & debate transcript

Description

TNF-α/IL-6 regulate glymphatic clearance of amyloid-β and tau. Inhibiting these cytokines impairs waste clearance in AD brains while providing anti-inflammatory benefits in cardiovascular tissues that don't rely on glymphatic function.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["TNF-alpha IL-6 Signaling in AD
Astrocyte Reactivity"] B["AQP4 Aquaporin-4 Regulation
Astrocytic Endfeet Polarization"] C["Glymphatic Flow Rate
Interstitial Fluid Exchange"] D["Amyloid-beta Tau Clearance
Waste Transport to Lymphatics"] E["Anti-Cytokine Therapy
TNF-alpha IL-6 Inhibition"] F["AQP4 Perivascular Expression Altered
Glymphatic Function Impaired"] G["Amyloid-beta Tau Accumulate
Reduced Clearance Rate"] H["AD Pathology Worsened
Sleep-Dependent Clearance Disrupted"] A --> B B --> C C --> D E -.->|"disrupts AQP4 regulation"| B E --> F F --> G G --> H style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.50 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.50 (6%) Data Avail. 0.50 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.455 composite
8 citations 8 with PMID 8 medium Validation: 0% 5 supporting / 3 opposing
For (5)
5
3
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
3
1
MECH 4CLIN 3GENE 1EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
The glymphatic pathway in neurological disorders.SupportingCLINLancet Neurol MEDIUM2018-PMID:30353860-
High-intensity interval training ameliorates Alzhe…SupportingMECHTheranostics MEDIUM2023-PMID:37351177-
Rutin prevents tau pathology and neuroinflammation…SupportingMECHJ Neuroinflamma… MEDIUM2021-PMID:34116706-
Impaired glymphatic function and clearance of tau …SupportingGENEBrain MEDIUM2020-PMID:32705145-
Exosomes derived from bone-marrow mesenchymal stem…SupportingCLINJ Neuroinflamma… MEDIUM2022-PMID:35130907-
The glymphatic pathway in neurological disorders.OpposingCLINLancet Neurol MEDIUM2018-PMID:30353860-
Aquaporin-4 in glymphatic system, and its implicat…OpposingMECHNeurobiol Dis MEDIUM2023-PMID:36796590-
Aquaporin-4-dependent glymphatic solute transport …OpposingMECHElife MEDIUM2018-PMID:30561329-
Legacy Card View — expandable citation cards

Supporting Evidence 5

The glymphatic pathway in neurological disorders. MEDIUM
Lancet Neurol · 2018 · PMID:30353860
High-intensity interval training ameliorates Alzheimer's disease-like pathology by regulating astrocyte phenot… MEDIUM
High-intensity interval training ameliorates Alzheimer's disease-like pathology by regulating astrocyte phenotype-associated AQP4 polarization.
Theranostics · 2023 · PMID:37351177
Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer's disease. MEDIUM
J Neuroinflammation · 2021 · PMID:34116706
Impaired glymphatic function and clearance of tau in an Alzheimer's disease model. MEDIUM
Brain · 2020 · PMID:32705145
Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improv… MEDIUM
Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology.
J Neuroinflammation · 2022 · PMID:35130907

Opposing Evidence 3

The glymphatic pathway in neurological disorders. MEDIUM
Lancet Neurol · 2018 · PMID:30353860
Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. MEDIUM
Neurobiol Dis · 2023 · PMID:36796590
Aquaporin-4-dependent glymphatic solute transport in the rodent brain. MEDIUM
Elife · 2018 · PMID:30561329
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-09 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on the clinical paradox of TNF-α and IL-6 inhibitor failures in Alzheimer's disease despite their cardiovascular success, I'll generate novel therapeutic hypotheses that could explain these mechanistic differences:

Hypothesis 1: CNS-Peripheral Cytokine Compartmentalization

Description: The blood-brain barrier creates distinct cytokine microenvironments where peripheral TNF-α/IL-6 inhibition fails to reach therapeutic concentrations in brain parenchyma, while cardiovascular tissues respond to systemic levels. Brain-specific delivery systems or BBB-penetrating variants could overco

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

I'll critically evaluate each hypothesis, identifying specific weaknesses, counter-evidence, and suggesting experiments to test or falsify them.

Hypothesis 1: CNS-Peripheral Cytokine Compartmentalization

Specific Weaknesses:

  • Oversimplifies BBB permeability - many biologics do achieve some CNS penetration
  • Ignores that intrathecal studies have also shown mixed results with anti-TNF therapy
  • Assumes therapeutic failure is solely due to insufficient CNS concentrations without considering that achieved levels might be adequate but still ineffective
  • Doesn't account for CNS production

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

I'll assess the practical feasibility of each hypothesis, focusing on druggability, existing compounds, competitive landscape, and development practicalities.

Hypothesis 1: CNS-Peripheral Cytokine Compartmentalization

Revised Confidence: 0.5

Druggability Assessment: MODERATE

  • BBB Transporters (LRP1, RAGE): Challenging targets - LRP1 is a large, complex receptor with multiple ligands. RAGE has been targeted but with limited success.
  • CNS-targeted anti-TNF/IL-6: More feasible - several approaches exist including brain-penetrating antibodies and nanoparticle delivery.

###

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.460.490.51 0.54 0.43 2026-04-212026-04-252026-04-28 Market PriceScoreevidencedebate 8 events
7d Trend
Stable
7d Momentum
▲ 6.1%
Volatility
Medium
0.0492
Events (7d)
7

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (7)

The glymphatic pathway in neurological disorders.
Lancet Neurol (2018) · PMID:30353860
No extracted figures yet
No extracted figures yet
Impaired glymphatic function and clearance of tau in an Alzheimer's disease model.
Brain : a journal of neurology (2020) · PMID:32705145
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
5

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.505

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for AQP4.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for AQP4 →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (16)

AQP4IL6LRP1NLRP3SLC16A7TNFTNFRSF1Balzheimer_diseaseblood_brain_barrierglucose_metabolismglymphatic_clearanceglymphatic_systeminflammasome_activationlactate_shuttlingneuroinflammationsynaptic_plasticity

Related Hypotheses

SASP-Driven Aquaporin-4 Dysregulation
Score: 0.782 | neurodegeneration
Aquaporin-4 Polarization Rescue
Score: 0.732 | neurodegeneration
CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic Failure in Early Neurodegeneration
Score: 0.705 | None
Loss of AQP4 Polarization Impairs Glymphatic Perivascular Influx, Causing Metabolite Accumulation
Score: 0.690 | neurodegeneration
Time-Limited AQP4 Inhibition for Acute Cytotoxic Edema Followed by Therapeutic Release
Score: 0.690 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (13 edges)

activates (1)

NLRP3inflammasome_activation

causes (1)

neuroinflammationalzheimer_disease

enhances (3)

TNFneuroinflammationIL6neuroinflammationNLRP3neuroinflammation

modulates (1)

SLC16A7lactate_shuttling

regulates (7)

TNFRSF1Bsynaptic_plasticityLRP1blood_brain_barrierAQP4glymphatic_systemTNFglymphatic_clearanceIL6glymphatic_clearance
▸ Show 2 more

Mechanism Pathway for AQP4

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    TNFRSF1B["TNFRSF1B"] -->|regulates| synaptic_plasticity["synaptic_plasticity"]
    LRP1["LRP1"] -->|regulates| blood_brain_barrier["blood_brain_barrier"]
    SLC16A7["SLC16A7"] -->|modulates| lactate_shuttling["lactate_shuttling"]
    AQP4["AQP4"] -->|regulates| glymphatic_system["glymphatic_system"]
    NLRP3["NLRP3"] -->|activates| inflammasome_activation["inflammasome_activation"]
    neuroinflammation["neuroinflammation"] -->|causes| alzheimer_disease["alzheimer_disease"]
    TNF["TNF"] -->|enhances| neuroinflammation_1["neuroinflammation"]
    IL6["IL6"] -->|enhances| neuroinflammation_2["neuroinflammation"]
    NLRP3_3["NLRP3"] -->|enhances| neuroinflammation_4["neuroinflammation"]
    TNF_5["TNF"] -->|regulates| glymphatic_clearance["glymphatic_clearance"]
    IL6_6["IL6"] -->|regulates| glymphatic_clearance_7["glymphatic_clearance"]
    TNF_8["TNF"] -->|regulates| glucose_metabolism["glucose_metabolism"]
    style TNFRSF1B fill:#ce93d8,stroke:#333,color:#000
    style synaptic_plasticity fill:#4fc3f7,stroke:#333,color:#000
    style LRP1 fill:#ce93d8,stroke:#333,color:#000
    style blood_brain_barrier fill:#4fc3f7,stroke:#333,color:#000
    style SLC16A7 fill:#ce93d8,stroke:#333,color:#000
    style lactate_shuttling fill:#81c784,stroke:#333,color:#000
    style AQP4 fill:#ce93d8,stroke:#333,color:#000
    style glymphatic_system fill:#81c784,stroke:#333,color:#000
    style NLRP3 fill:#ce93d8,stroke:#333,color:#000
    style inflammasome_activation fill:#81c784,stroke:#333,color:#000
    style neuroinflammation fill:#4fc3f7,stroke:#333,color:#000
    style alzheimer_disease fill:#ef5350,stroke:#333,color:#000
    style TNF fill:#ce93d8,stroke:#333,color:#000
    style neuroinflammation_1 fill:#4fc3f7,stroke:#333,color:#000
    style IL6 fill:#ce93d8,stroke:#333,color:#000
    style neuroinflammation_2 fill:#4fc3f7,stroke:#333,color:#000
    style NLRP3_3 fill:#ce93d8,stroke:#333,color:#000
    style neuroinflammation_4 fill:#4fc3f7,stroke:#333,color:#000
    style TNF_5 fill:#ce93d8,stroke:#333,color:#000
    style glymphatic_clearance fill:#81c784,stroke:#333,color:#000
    style IL6_6 fill:#ce93d8,stroke:#333,color:#000
    style glymphatic_clearance_7 fill:#81c784,stroke:#333,color:#000
    style TNF_8 fill:#ce93d8,stroke:#333,color:#000
    style glucose_metabolism fill:#81c784,stroke:#333,color:#000

3D Protein Structure

🧬 AQP4 — PDB 7O3C Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Why do systemic anti-inflammatory drugs fail in AD despite cardiovascular efficacy if neuroinflammation is central?

clinical neurology | 2026-04-08 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

Compensatory Cytokine Network Activation
Score: 0.46 · NLRP3
Synaptic Plasticity Preservation
Score: 0.46 · TNFRSF1B
Microglial State-Dependent Cytokine Function
Score: 0.46 · TREM2
Astrocyte-Neuron Metabolic Coupling
Score: 0.46 · SLC16A7
CNS-Peripheral Cytokine Compartmentalization
Score: 0.46 · LRP1
→ View all analysis hypotheses
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.